Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 830

Results For "IT"

10318 News Found

Biocon Q1FY23 consolidated PAT falls QoQ at Rs. 144.4 Cr
News | July 28, 2022

Biocon Q1FY23 consolidated PAT falls QoQ at Rs. 144.4 Cr

Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.


Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr
News | July 28, 2022

Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr

Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.


Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr
News | July 28, 2022

Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr

Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022


Bulk Drug Park in the country :PIB
Policy | July 27, 2022

Bulk Drug Park in the country :PIB

The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park


Tealium launches customer data platform for pharma
Digitisation | July 27, 2022

Tealium launches customer data platform for pharma

Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors


Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr
News | July 27, 2022

Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr

Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.


Pharmaceuticals industry under Atmanirbhar Bharat programme
Policy | July 27, 2022

Pharmaceuticals industry under Atmanirbhar Bharat programme

India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.


Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study
Clinical Trials | July 27, 2022

Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study

The NTM-001 Phase I clinical study is expected to be completed by the end of 2022


Lupin receives approval from U.S. FDA for Azilsartan Medoxomil Tablets
Drug Approval | July 26, 2022

Lupin receives approval from U.S. FDA for Azilsartan Medoxomil Tablets

The product will be manufactured at Lupin's facility in Nagpur, India.